Gilead to Present Phase 3 Livdelzi Data in Primary Biliary Cholangitis at Liver Meeting 2026

By Public Technologies
  • Gilead Sciences will present new Livdelzi and Hepcludex data at The Liver Meeting, November 5-9, 2026, in Denver.
  • Phase 3 IDEAL results will examine Livdelzi’s effect on a liver disease marker in adults with primary biliary cholangitis.
  • Long-term Livdelzi analyses report sustained efficacy and safety through five years; separate findings show clinically meaningful fatigue improvement.
  • Hepcludex research will assess sustained treatment response in chronic hepatitis delta; another analysis suggests improvement in liver-related hypertension for some patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610220800BIZWIRE_USPR_____20261021_BW867668) on October 22, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.